Main content

    MMC Available Clinical Trials

    Breadcrumbs Navigation: Cancer Services > Treatment > Clinical Trials at MMC > You are here: MMC Available Trials

     


    Note: As of April 2015


    BILIARY:

    SWOG S1310
    Randomized Phase II Trial of Single Agent MEK Inhibitor (GSK1120212) vs. 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer.

    Back to top


    BRAIN:

    N107C
    Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease.

    RTOG 1205
    Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma.

    Back to top


    BREAST:

    NSABP B-51/ RTOG 1304
    A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy.

    RTOG 1119
    Phase II Randomized Study of Whole Brain Radiotherapy in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer.

    S1007
    A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less.

    SWOG 1202
    A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer.

    SWOG 1207 / NSABP B-53
    Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer (Breast Cancer Study – evaluating everolimus with endocrine therapy).

    Back to top


    GASTROINTESTINAL:

    RTOG 0848
    A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.

    RTOG 1010
    A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of Her2-Overexpressing Esophageal Adenocarcinoma.

    CALGB 80702
    A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer.

    SWOG S0820
    A Phase III Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES).

    Back to top


    GENITOURINARY:

    RTOG 0815
    A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer.

    RTOG 0924
    Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial.

    S0931
    EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study.

    S1216
    A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer.

    Back to top


    Gynecologic

    GOG-0213
    A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer.

    GOG-0225
    Diet and Physical Activity Change or Usual Care in Improving Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

    GOG-0238
    A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterus Corpus.

    GOG-0263
    A Randomized Phase III Clinical Trial of Adjuvant Radiation vs. Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy.

    Back to top


    HEAD & NECK:

    NRG-HN002
    A Randomized Phase II Trial For Patients with p16 Positive, Non-Smoking Associated, Lococregionally Advanced Oropharyngeal Cancer.

    RTOG 0920
    A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer.

    RTOG 1216
    Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Cetuximab and Docetaxel for High-Risk Squamous Cell Cancer of the Head and Neck.

    Back to top


    Leukemia:

    Alliance A041202
    A Randomized Phase III Study of Bendamustine Plus Rituximab vs. Ibrutinib Plus Rituximab vs. Ibrutinib Alone in Untreated Older Patients (> 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL).

    Back to top


    LYMPHOMA

    E1412
    Randomized phase II Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma.

    E4512
    A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer; Crizotinib vs. Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein.

    Back to top


    THORAX:



    Alliance A081105
    Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC).

    Alliance A151216
    Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST).

    CALGB 30610
    Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide.

    E5508
    A Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed or Both Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Stage Non-Squamous Non-Small Cell Lung Cancer.

    Back to top

    Contacts

    For additional information regarding the above Clinical Trials,
    please contact one of our Cancer Research Coordinators:

    Elise Fredeking, RN, BSN, OCN
    209-526-4500, ext. 6192

    Denise Galbawy, RN, BSN, OCN, CCRC
    209-572-7116.